Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions

Perrine Roux, Caroline Lions, Laurent Michel, Marion Mora, Jean-Pierre Daulouède, Fabienne Marcellin, Bruno Spire, Alain Morel, Patrizia M Carrieri, ANRS Methaville study group, P M Carrieri, A Morel, L Michel, M Mora, P Roux, J F Aubertin, S Robinet, J C Desenclos, J Cohen, A Herszkowicz, C Paul, I Porteret, T Sainte Marie, Achard, Aubertin, Balteau Bijeau, Bartolo, Bibette, Biderman, Bry, Cadart, Dewost, Daulouede, Gassmann, Guena, Guillet, Gutekunst, Herouin, Herran, Jacob, Kerloc'h, Khouri, Lasalarié, Lavignasse, Magnin, Marre, Mauraycaplanne, Michel, Alain Morel, Nemayechi, Paillou, Partouche, Petit, Pouclet, Raulin, Regard, Roch, Rouille, Truffy, Vergez, Vincent, Wajsbrot, J Bachellier, P Beauverie, J P Couteron, C Marty-Double, M Vray, R Baker, H Catania, M Gossop, R Haemmig, M Torrens, A Wodak, M P Carrieri, L Michel, M Mora, P Roux, G Maradan, J Biemar, S Huguet, P Kurkdji, C Taieb, J Cohen, C Giovannini, M P Kissikian, J C Desenclos, N Job-Spira, V Dore, C Paul, I Porteret, N Richard, A Herszkowicz, N Prisse, F Olivet, J Arditti, Perrine Roux, Caroline Lions, Laurent Michel, Marion Mora, Jean-Pierre Daulouède, Fabienne Marcellin, Bruno Spire, Alain Morel, Patrizia M Carrieri, ANRS Methaville study group, P M Carrieri, A Morel, L Michel, M Mora, P Roux, J F Aubertin, S Robinet, J C Desenclos, J Cohen, A Herszkowicz, C Paul, I Porteret, T Sainte Marie, Achard, Aubertin, Balteau Bijeau, Bartolo, Bibette, Biderman, Bry, Cadart, Dewost, Daulouede, Gassmann, Guena, Guillet, Gutekunst, Herouin, Herran, Jacob, Kerloc'h, Khouri, Lasalarié, Lavignasse, Magnin, Marre, Mauraycaplanne, Michel, Alain Morel, Nemayechi, Paillou, Partouche, Petit, Pouclet, Raulin, Regard, Roch, Rouille, Truffy, Vergez, Vincent, Wajsbrot, J Bachellier, P Beauverie, J P Couteron, C Marty-Double, M Vray, R Baker, H Catania, M Gossop, R Haemmig, M Torrens, A Wodak, M P Carrieri, L Michel, M Mora, P Roux, G Maradan, J Biemar, S Huguet, P Kurkdji, C Taieb, J Cohen, C Giovannini, M P Kissikian, J C Desenclos, N Job-Spira, V Dore, C Paul, I Porteret, N Richard, A Herszkowicz, N Prisse, F Olivet, J Arditti

Abstract

Background: One important public health issue associated with opioid use today is the risk of hepatitis C (HCV) infection. Although methadone maintenance may help to decrease HCV-related risk practices, HCV risk behaviors persist and are strongly associated with specific substance use patterns, mental status and social context. The ANRS-Methaville study gave us the opportunity to better disentangle the different relationships between these various factors and HCV risk practices.

Methods: The ANRS-Methaville multisite randomized trial was designed to assess the feasibility of initiating methadone in primary care by comparing it with methadone initiation in specialized centers. This study recruited 195 participants initiating methadone maintenance and followed up for 12 months. Longitudinal data from this trial was used to acquire a greater understanding of HCV risk practices and their pattern of correlates in this population. We selected 176 patients who had data on HCV risk practices at M0 and M12, accounting for 312 visits. HCV risk practices were defined as follows: sharing needles or syringes, sharing drug paraphernalia, getting a tattoo or having a piercing in a non-professional context, sharing toiletry items. To identify factors associated with HCV risk practices, we performed a mixed logistic regression analysis.

Results: HCV risk practices were reported by 19% and 15% of participants at baseline and M12, respectively. After adjustment for age, cocaine use and alcohol dependence as well as suicidal risk, living in a couple with a non-drug user and in a couple with a drug user were both independent predictors of HCV risk practices (OR[CI95%] = 4.16 [1.42-12.12]; OR[CI95%] = 9.85 [3.13-31.06], respectively).

Conclusions: Identifying individuals at risk of HCV transmission during methadone treatment such as stimulant users, alcohol dependent individuals, and those at suicidal risk is necessary to optimize response to treatment. Innovative prevention approaches tailored to couples are also urgently needed and could decrease HCV-risk in this population. The trial is registered with the French Agency of Pharmaceutical Products (ANSM) under the number 2008-A0277-48, the European Union Drug Regulating Authorities Clinical Trials. Number Eudract 2008-001338-28, the ClinicalTrials.gov Identifier: NCT00657397 and the International Standard Randomised Controlled Trial Number Register ISRCTN31125511.

References

    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2:CD002209.
    1. Smyth BP, Barry J, Lane A, Cotter M, O’Neill M, Quinn C, Keenan E. In-patient treatment of opiate dependence: medium-term follow-up outcomes. Br J Psychiatry. 2005;187:360–365. doi: 10.1192/bjp.187.4.360.
    1. Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid-dependent people: cohort study. Addiction. 2011;106:2186–2192. doi: 10.1111/j.1360-0443.2011.03575.x.
    1. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107:1984–1995. doi: 10.1111/j.1360-0443.2012.03932.x.
    1. van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990;162:823–826. doi: 10.1093/infdis/162.4.823.
    1. Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, Taylor A. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat. 2014;21:25–32. doi: 10.1111/jvh.12117.
    1. Aaron S, McMahon JM, Milano D, Torres L, Clatts M, Tortu S, Mildvan D, Simm M. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis. 2008;47:931–934. doi: 10.1086/591699.
    1. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis. 2012;54:1167–1178. doi: 10.1093/cid/cir991.
    1. Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat. 2000;7:93–103. doi: 10.1046/j.1365-2893.2000.00203.x.
    1. Tiftikci A, Atug O, Tozun N. Awareness of hepatitis C virus transmission routes among patients, their household contacts and health care staff: does perception match the reality? Turk J Gastroenterol. 2009;20:104–107.
    1. Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, Salimi S, Hadian M. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon. 2013;13(8):e12411.
    1. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454–1462. doi: 10.1111/j.1360-0443.2007.01912.x.
    1. Roux PD, Michel LD, Cohen J, Mora M, Morel A, Aubertin JF, Desenclos JC, Spire B, Carrieri PM. ANRS Methaville Study Group. Initiation of Methadone in primary care (ANRS-Methaville): a phase III randomized intervention trial. BMC Public Health. 2012;12:488. doi: 10.1186/1471-2458-12-488.
    1. Johnson JA, Lee A, Vinson D, Seale JP. Use of AUDIT-based measures to identify unhealthy alcohol use and alcohol dependence in primary care: a validation study. Alcohol Clin Exp Res. 2013;37(Suppl 1):E253–E259.
    1. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87:733–742. doi: 10.1111/j.1360-0443.1992.tb02719.x.
    1. Fry CL, Lintzeris N. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ) Addiction. 2003;98:171–178. doi: 10.1046/j.1360-0443.2003.00207.x.
    1. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, Delamare C, Cyran C, Van Hoenacker AF, Frémaux D, Josse P, Emmanuelli J, Le Strat Y, Desenclos JC, Filoche B. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect. 2004;132:699–708. doi: 10.1017/S095026880400247X.
    1. Beck AT, Weishaar ME. Suicide risk assessment and prediction. Crisis. 1990;11:22–30.
    1. Huo D, Bailey SL, Garfein RS, Ouellet LJ. Changes in the sharing of drug injection equipment among street-recruited injection drug users in Chicago, Illinois, 1994–1996. Subst Use Misuse. 2005;40:63–76. doi: 10.1081/JA-200030495.
    1. Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999) J Acquir Immune Defic Syndr. 2001;27:71–78. doi: 10.1097/00126334-200105010-00012.
    1. Mackesy-Amiti ME, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, Latka MH, Garfein RS. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav. 2013;17:2075–2083. doi: 10.1007/s10461-012-0373-0.
    1. Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Perlman DC, Hagan H, Cooper HL. Transitions from injecting to non-injecting drug use: potential protection against HCV infection. J Subst Abuse Treat. 2014;46:325–331. doi: 10.1016/j.jsat.2013.09.004.
    1. Macias J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, Merchante N, Corzo JE, Pineda JA. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008;28:781–786. doi: 10.1111/j.1478-3231.2008.01688.x.
    1. Buchanan D, Tooze JA, Shaw S, Kinzly M, Heimer R, Singer M. Demographic, HIV risk behavior, and health status characteristics of “crack” cocaine injectors compared to other injection drug users in three New England cities. Drug Alcohol Depend. 2006;81:221–229. doi: 10.1016/j.drugalcdep.2005.07.011.
    1. Oliveira LG, Ponce Jde C, Nappo SA. Crack cocaine use in Barcelona: a reason of worry. Subst Use Misuse. 2010;45:2291–2300. doi: 10.3109/10826081003682883.
    1. Wilkins L, Bissell P, Meier PS. Risky injecting practices associated with snowballing: a qualitative study. Drug Alcohol Rev. 2010;29:256–262. doi: 10.1111/j.1465-3362.2009.00142.x.
    1. Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA. BHIVES Collaborative. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S14–S21.
    1. Le Marchand C, Evans J, Page K, Davidson PJ, Hahn JA. Hazardous alcohol consumption among young adult IDU and its association with high risk behaviors. Drug Alcohol Depend. 2013;127:143–149. doi: 10.1016/j.drugalcdep.2012.06.024.
    1. Field CA, Cochran G, Caetano R. Treatment utilization and unmet treatment need among Hispanics following brief intervention. Alcohol Clin Exp Res. 2012;37:300–307.
    1. Zule WA, Costenbader EC, Coomes CM, Wechsberg WM. Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health. 2009;99(Suppl 1):S180–S186.
    1. Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop D, Mokri A. Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence. Subst Abuse Rehabil. 2012;3:37–43.
    1. Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior–outcomes of a randomized trial. Drug Alcohol Depend. 2013;133:376–382. doi: 10.1016/j.drugalcdep.2013.06.024.
    1. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor A, De Angelis D, Cameron S, Parry J, Lyons M, Goldberg D, Allen E, Hickman M. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106:1978–1988. doi: 10.1111/j.1360-0443.2011.03515.x.
    1. Ng MH, Chou JY, Chang TJ, Lee PC, Shao WC, Lin TY, Chen VC, Gossop M. High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan. Addict Behav. 2013;38:2089–2093. doi: 10.1016/j.addbeh.2013.01.010.
    1. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction. 2005;100:1690–1700. doi: 10.1111/j.1360-0443.2005.01271.x.
    1. Zhuang X, Liang Y, Chow EP, Wang Y, Wilson DP, Zhang L. HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis. BMC Infect Dis. 2012;12:130. doi: 10.1186/1471-2334-12-130.
    1. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence–a comparison between injection and noninjection drug users in New York City. J Urban Health. 2004;81:20–24. doi: 10.1093/jurban/jth084.
    1. Darke S, Williamson A, Ross J, Teesson M. Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS) Drug Alcohol Depend. 2005;78:177–186. doi: 10.1016/j.drugalcdep.2004.10.009.
    1. Bradvik L, Frank A, Hulenvik P, Medvedeo A, Berglund M. Heroin addicts reporting previous heroin overdoses also report suicide attempts. Suicide Life Threat Behav. 2007;37:475–481. doi: 10.1521/suli.2007.37.4.475.
    1. Lowry R, Crosby AE, Brener ND, Kann L. Suicidal thoughts and attempts among u.s. High school students: trends and associated health-risk behaviors, 1991-2011. J Adolesc Health. 2014;54:100–108. doi: 10.1016/j.jadohealth.2013.07.024.
    1. Bohnert AS, Roeder K, Ilgen MA. Unintentional overdose and suicide among substance users: a review of overlap and risk factors. Drug Alcohol Depend. 2010;110:183–192. doi: 10.1016/j.drugalcdep.2010.03.010.
    1. Sarin E, Singh B, Samson L, Sweat M. Suicidal ideation and HIV risk behaviors among a cohort of injecting drug users in New Delhi, India. Subst Abuse Treat Prev Policy. 2013;8:2. doi: 10.1186/1747-597X-8-2.
    1. de Carvalho-Mello IM, Filho JE, Gomes-Gouvea MS, de Mello MF, de Queiroz AT, Pinho JR, Carrilho FJ. Molecular evidence of horizontal transmission of hepatitis C virus within couples. J Gen Virol. 2010;91:691–696. doi: 10.1099/vir.0.015594-0.
    1. El-Bassel N, Gilbert L, Terlikbayeva A, Wu E, Beyrer C, Shaw S, Hunt T, Ma X, Chang M, Ismayilova L, Tukeyev M, Zhussupov B, Rozental Y. HIV among injection drug users and their intimate partners in Almaty, Kazakhstan. AIDS Behav. 2013;17:2490–2500. doi: 10.1007/s10461-013-0484-2.
    1. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2011;107:1057–1065.
    1. Bryant J, Brener L, Hull P, Treloar C. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug Alcohol Depend. 2010;107:182–187. doi: 10.1016/j.drugalcdep.2009.10.007.
    1. Dwyer R, Fraser S, Treloar C. Doing things together? Analysis of health education materials to inform hepatitis C prevention among couples. Addiction Research & Theory. 2011;19:352–361. doi: 10.3109/16066359.2011.562619.
    1. Simmons J, Rajan S, McMahon JM. Retrospective accounts of injection initiation in intimate partnerships. Int J Drug Policy. 2012;23:303–311. doi: 10.1016/j.drugpo.2012.01.009.
    1. Harris M, Rhodes T. Injecting practices in sexual partnerships: hepatitis C transmission potentials in a ‘risk equivalence’ framework. Drug Alcohol Depend. 2013;132:617–623. doi: 10.1016/j.drugalcdep.2013.04.012.
    1. Wang L, Wei X, Wang X, Li J, Li H, Jia W. Long-term effects of methadone maintenance treatment with different psychosocial intervention models. PLoS One. 2014;9:e87931. doi: 10.1371/journal.pone.0087931.
    1. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253–263. doi: 10.1016/S0376-8716(98)00028-3. discussion 267-258.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever